Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022140706 - IMMUNE-REGULATORY LI-KEY PEPTIDE VACCINES FOR PROPHYLAXIS AND LONG-TERM PROTECTION AGAINST SARS-COV-2 INFECTION AND COVID-19 DISEASE

Publication Number WO/2022/140706
Publication Date 30.06.2022
International Application No. PCT/US2021/065178
International Filing Date 24.12.2021
IPC
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
C07K 19/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
G01N 33/569 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
G16B 15/30 2019.1
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
15ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
30Drug targeting using structural data; Docking or binding prediction
G16B 30/10 2019.1
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
30ICT specially adapted for sequence analysis involving nucleotides or amino acids
10Sequence alignment; Homology search
G16B 35/20 2019.1
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
35ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
20Screening of libraries
CPC
A61K 2039/605
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
60characteristics by the carrier linked to the antigen
6031Proteins
605MHC molecules or ligands thereof
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
C12N 2770/20034
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2770ssRNA Viruses positive-sense
00011ssRNA Viruses positive-sense
20011Coronaviridae
20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
G16B 15/30
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
15ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
30Drug targeting using structural data; Docking or binding prediction
Applicants
  • PURCELL, Richard, D. [US]/[US]
  • TERRELL, Jason, B. [US]/[US]
  • VON HOFE, Eric, H. [US]/[US]
Inventors
  • PURCELL, Richard, D.
  • TERRELL, Jason, B.
  • VON HOFE, Eric, H.
Agents
  • KING, Jeffery, J.
Priority Data
63/130,82227.12.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) IMMUNE-REGULATORY LI-KEY PEPTIDE VACCINES FOR PROPHYLAXIS AND LONG-TERM PROTECTION AGAINST SARS-COV-2 INFECTION AND COVID-19 DISEASE
(FR) VACCINS À BASE DE PEPTIDE LI-KEY À RÉGULATION IMMUNITAIRE POUR LA PROPHYLAXIE ET LA PROTECTION À LONG TERME CONTRE L'INFECTION PAR SRAS-COV-2 ET LA MALADIE COVID-19
Abstract
(EN) The disclosure details methods for producing peptide-based vaccines for immunizing mammalian subjects against the SARS Coronavirus SARS-CoV-2, and additionally describes peptide vaccines and methods for immunizing mammalian subjects, including humans, to elicit a protective immune response against SARS-CoV-2 and to prevent or reduce the severity of COVID- 19 disease. Additionally, the disclosure provides methods and compositions for making and using li-Key peptide fusions with SARS-CoV-2 antigenic peptides to make immunogenic Ii-Key-SARS-CoV-2 peptide hybrid constructs exhibiting increased MHC presentation-based immune cell activation useful for vaccines against SARS-CoV-2.
(FR) L'invention concerne des procédés de production de vaccins à base de peptide permettant d’immuniser des sujets mammifères contre le Coronavirus SARS-CoV-2, et concerne en outre des vaccins peptidiques et des procédés pour immuniser des sujets mammifères, y compris des êtres humains, pour déclencher une réponse Immunitaire protectrice contre le SARS-CoV-2 et pour prévenir ou réduire la gravité de la maladie COVID-19. De plus, l'invention concerne des procédés et des compositions permettant de fabriquer et d’utiliser des fusions de peptides li-Key avec des peptides antigéniques du SARS-CoV-2 pour fabriquer des constructions hybrides peptidiques Ii-Key-SARS-CoV-2 immunogènes présentant une activation accrue des cellules immunitaires basée sur la présentation du complexe majeur d'histocompatibilité (CMH) utile pour des vaccins contre le SARS-CoV-2.
Latest bibliographic data on file with the International Bureau